½ÃÀ庸°í¼­
»óǰÄÚµå
1799596

¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼® - Á¦Ç°º°, ±â¼úº°, Áö¿ªº° ¿¹Ãø(2025-2035³â)

Global Immune Repertoire Sequencing Market Size Study & Forecast, by Product (Instrument, Software, Assay Kit & Reagent) and Technology (Sequencing, Bioinformatics) and Regional Forecasts 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ ¾à 3¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£(2025-2035³â) Áß CAGR 9.60%·Î °ßÁ¶ÇÏ°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½ÌÀº T ¼¼Æ÷¿Í B ¼¼Æ÷ ¼ö¿ëüÀÇ ´Ù¾ç¼ºÀ» ÇØµ¶Çϴ ÷´Ü ±â¼úÀ» Æ÷ÇÔÇÏ¿© ÀûÀÀ ¸é¿ª, Áúº´ ¸ÞÄ¿´ÏÁò ¹× Ä¡·á °³¹ß¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸é¿ªÇÐ ¿¬±¸ ÅõÀÚ Áõ°¡, ÀÓ»ó ¹× ¿¬±¸ ȯ°æ¿¡¼­ Â÷¼¼´ë ½ÃÄö½Ì(NGS) ±â¼úÀÇ ±Þ¼ÓÇÑ ÅëÇÕÀÔ´Ï´Ù. °Ô´Ù°¡, °í󸮷® ½ÃÄö½Ì Ç÷§ÆûÀÇ º¸±ÞÀº ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ÁÖµµ ºÐ¼® Åø°ú °áÇÕÇÏ¿© ¸é¿ªÇÁ·ÎÆÄÀϸµÀÇ ±íÀÌ ¹× ÇØ»óµµ¸¦ ´ëÆø Çâ»ó½ÃÄÑ ´Ù¾çÇÑ ¿ëµµ·Î ½ÃÀå µµÀÔÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ÀǾàǰ ¹× °³¹ßÀÇ Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÄö½Ì Á¢±Ù¹ýÀº ¸é¿ª ¹ÝÀÀÀ» ÀÌÇØÇϰí Ŭ·Ð È®ÀåÀ» ÃßÀûÇϸç Ç×ü¿Í T ¼¼Æ÷ÀÇ ·¹ÆÛÅ丮¸¦ Ư¼ºÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÃÖ±Ù »ê¾÷ ºÐ¼®¿¡ µû¸£¸é ¼¼°èÀÇ ¸é¿ªÇÐ ¿¬±¸°³¹ßºñ´Â °è¼Ó Áõ°¡Çϰí ÀÖÀ¸¸ç, ¸é¿ª ·¹ÆÛÅ丮 ±â¼úÀÇ ¼ºÀå ±âȸ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´ÉÀ» ÀÌ¿ëÇÑ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ À¶ÇÕ°ú TCR ¹× BCR ÇÁ·ÎÆÄÀϸµÀ» À§ÇÑ ºÐ¼® ŰƮ ¹× ½Ã¾àÀÇ Áøº¸´Â °³ÀÎÈ­ Ä¡·áÁ¦¿Í ¹é½Å °³¹ßÀÇ »õ·Î¿î °¡´É¼ºÀ» ²ø¾î³»°í ÀÖ½À´Ï´Ù. ±×·¯³ª ºñ¿ë È¿À²ÀûÀÎ ´ëü Áø´Ü¿¡ ÁßÁ¡À» µÎ°í ´ëü ¸é¿ª ÇÁ·ÎÆÄÀÏ ¸µ Àü·«À» äÅÃÇϸé 2025-2035³â ½ÃÀå È®´ë¿¡ Àû´çÇÑ Á¦¾àÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù.

Áö¿ªº° ºÐ¼®¿¡ µû¸£¸é, ºÏ¹Ì´Â È®¸³µÈ »ý¸í°øÇаú Á¦¾à ÀÎÇÁ¶ó°¡ ÀÖ¾î ¸é¿ªÇÐ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±ÝÀÌ Ç³ºÎÇϰí, °í󸮷® ½ÃÄö½Ì Ç÷§ÆûÀÌ ÀÏÂïºÎÅÍ Ã¤¿ëµÇ°í Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È Áö¹èÀûÀÎ ÁöÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´Àº ¶ÇÇÑ Á¤ºÎÀÇ °­·ÂÇÑ ÀÌ´Ï¼ÅÆ¼ºê, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ÁÖ¿ä ¾÷°è ±â¾÷ÀÇ Á¸Àç¿¡ ÈûÀÔ¾î Áß¿äÇÑ ½ÃÀåÀÌ µÇ¾ú½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº »ý¹°ÀÇÇבּ¸ È®´ë, â¾à ÅõÀÚ Áõ°¡, Áß±¹, Àεµ, ÀϺ» µîÀÇ Àӻ󿬱¸¼¾ÅÍ Áõ°¡·Î °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÇÑÆí ¶óÆ¾¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶¿Í °øµ¿ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¿¡ °ßÀÎµÇ¾î ²ÙÁØÇÑ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ¸ñÀûÀº ÃÖ±Ù ¿©·¯ ºÎ¹® ¹× ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ¹àÈ÷°í ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â ºÐ¼® ´ë»ó ±¹°¡¿¡¼­ ¾÷°èÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå Àü¸Á ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î ½ÃÀåÀÇ ÀáÀçÀûÀÎ ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ »ó¼¼ÇÑ ºÎ¹®¿Í ÇÏÀ§ ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå : ºÐ¼® ¹üÀ§ ¹× ¼ö¹ý

  • ºÐ¼® ¸ñÀû
  • ºÐ¼® ¹æ¹ý
    • ¿¹Ãø ¸ðµ¨
    • Ã¥»ó ºÐ¼®
    • ÇÏÇâ½Ä ¹× »óÇâ½Ä Á¢±Ù
  • ºÐ¼® ¼Ó¼º
  • ºÐ¼® ¹üÀ§
    • ½ÃÀå Á¤ÀÇ
    • ½ÃÀå ±¸ºÐ
  • ºÐ¼® ÀüÁ¦Á¶°Ç
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • ºÐ¼® ´ë»ó ±â°£

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • CEO/CXOÀÇ ÀÔÀå
  • Àü·«Àû ÀλçÀÌÆ®
  • ESG ºÐ¼®
  • ÁÖ¿ä ºÐ¼® °á°ú

Á¦3Àå ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå : ¿ªÇÐ ºÐ¼®

  • ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀåÀ» Á¿ìÇÏ´Â ½ÃÀå ¿ªÇÐ(2024-2035³â)
  • ¼ºÀå ÃËÁø¿äÀÎ
    • ¸é¿ª ÇÁ·ÎÆÄÀϸµ¿¡¼­ Â÷¼¼´ë ½ÃÄö½Ì(NGS)ÀÇ ±Þ¼ÓÇÑ µµÀÔ
    • ¸é¿ªÇÐ Á¶»ç ¹× Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÄö½Ì ºÐ¼®ÀÇ ¿öÅ©Ç÷ο쿡 °É¸®´Â ³ôÀº ÀÚº» ºñ¿ë ¹× »ùÇÃ´ç ºñ¿ë
    • µ¥ÀÌÅÍÀÇ º¹À⼺, Ç¥ÁØÈ­ÀÇ °úÁ¦, ±ÔÁ¦»óÀÇ Àå¾Ö¹°
  • ±âȸ
    • AI ¹× ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Ç÷§ÆûÀÇ ÅëÇÕ¿¡ ÀÇÇØ º¸´Ù ±íÀº ·¹ÆÛÅ丮 ÀλçÀÌÆ® ȹµæ
    • ÀÓ»ó ¹× Æ®·£½º·¹À̼ųΠ¿ëµµÀÇ È®´ë, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¬±¸¼¾ÅÍÀÇ ¼ºÀå

Á¦4Àå ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì »ê¾÷ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • °ø±ÞÀÚÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces : ¿¹Ãø ¸ðµ¨(2024-2035³â)
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ȯ°æÀû
    • ¹ýÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«(2025³â)
  • ½ÃÀå Á¡À¯À² ºÐ¼®(2024-2025³â)
  • ¼¼°èÀÇ °¡°Ý ºÐ¼® ¹× µ¿Çâ(2025³â)
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í ¹× °á·Ð

Á¦5Àå ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Á¦Ç°º°(2025-2035³â)

  • ½ÃÀå °³¿ä
  • ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ½ÇÀû : ÀáÀç·Â ºÐ¼®(2025³â)
  • ±â±â
  • ¼ÒÇÁÆ®¿þ¾î
  • ºÐ¼® ŰƮ ¹× ½Ã¾à(TCR ŰƮ, BCR ŰƮ)

Á¦6Àå ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ±â¼úº°(2025-2035³â)

  • ½ÃÀå °³¿ä
  • ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ½ÇÀû : ÀáÀç·Â ºÐ¼®(2025³â)
  • ½ÃÄö½Ì
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º

Á¦7Àå ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ¼­ºñ½ºº° ¹× ¿ëµµº°(2025-2035³â)

  • ½ÃÀå °³¿ä
  • ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ½ÇÀû : ÀáÀç·Â ºÐ¼®(2025³â)
  • ¼­ºñ½º : µ¥ÀÌÅÍ ºÐ¼®
  • ¿ëµµ : ¿¬±¸
  • ¿ëµµ : â¾à ¹× ÀǾàǰ °³¹ß

Á¦8Àå ¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°(2025-2035³â)

  • Áö¿ª ½ÃÀå ÇöȲ
  • ÁÖ¿ä ¼±Áø±¹ ¹× ½ÅÈï±¹
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • »ç¿ìµð¾Æ¶óºñ¾Æ(KSA)
    • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀåÀÇ Àü·«
  • Adaptive Biotechnologies Corp.
    • ±â¾÷ °³¿ä
    • ÁÖ¿ä °£ºÎ
    • ±â¾÷ÀÇ ½º³À¼¦
    • À繫½ÇÀû(µ¥ÀÌÅÍÀÇ À̿밡´É¼º¿¡ µû¶ó ´Ù¸§)
    • Á¦Ç° ¹× ¼­ºñ½º Æ÷Æ®Æú¸®¿À
    • ÃÖ±Ù °³¹ß
    • ½ÃÀå Àü·«
    • SWOT ºÐ¼®
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Roche Sequencing Solutions
  • 10x Genomics, Inc.
  • GenScript Biotech Corporation
  • New England Biolabs, Inc.
  • Agilent Technologies, Inc.
  • BD Biosciences
  • Tecan Group Ltd.
  • Oxford Nanopore Technologies
  • Fujifilm Cellular Dynamics, Inc.
  • Novogene Corporation
AJY 25.09.03

The Global Immune Repertoire Sequencing Market is valued at approximately USD 0.32 billion in 2024 and is projected to expand at a robust CAGR of 9.60% during the forecast period of 2025-2035. Immune repertoire sequencing encompasses advanced methodologies to decode the diversity of T-cell and B-cell receptors, thereby offering critical insights into adaptive immunity, disease mechanisms, and therapeutic development. This market growth is predominantly fueled by the rising demand for precision medicine, increased investments in immunology research, and the rapid integration of next-generation sequencing (NGS) technologies in both clinical and research settings. Moreover, the proliferation of high-throughput sequencing platforms, coupled with bioinformatics-driven analysis tools, has significantly enhanced the depth and resolution of immune profiling, further bolstering market adoption across diverse applications.

The surging need for innovative solutions in drug discovery and development has catalyzed the demand for immune repertoire sequencing services. These sequencing approaches are pivotal for understanding immune responses, tracking clonal expansions, and characterizing antibody and T-cell repertoires. According to recent industry analyses, global research and development expenditure in immunology continues to rise, fostering growth opportunities for immune repertoire technologies. Furthermore, the convergence of AI-driven bioinformatics, coupled with advancements in assay kits and reagents for TCR and BCR profiling, has unlocked new potential for personalized therapeutics and vaccine development. However, the growing emphasis on cost-effective diagnostic alternatives and the adoption of alternative immunoprofiling strategies may pose moderate constraints on market expansion during 2025-2035.

Regional analysis indicates that North America is projected to maintain a dominant position throughout the forecast period due to the presence of well-established biotech and pharmaceutical infrastructure, extensive funding in immunology research, and early adoption of high-throughput sequencing platforms. Europe also represents a significant market, supported by strong governmental initiatives, advanced healthcare infrastructure, and the presence of key industry players. Asia Pacific is anticipated to exhibit the fastest growth owing to expanding biomedical research, increasing investments in drug discovery, and a growing number of clinical research centers in countries such as China, India, and Japan. Meanwhile, Latin America and the Middle East & Africa are expected to witness steady growth, driven by rising awareness of personalized medicine and collaborative research initiatives.

Major market players included in this report are:

  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Adaptive Biotechnologies Corp.
  • Merck KGaA
  • Roche Sequencing Solutions
  • 10x Genomics, Inc.
  • GenScript Biotech Corporation
  • New England Biolabs, Inc.
  • Agilent Technologies, Inc.
  • BD Biosciences
  • Tecan Group Ltd.
  • Oxford Nanopore Technologies
  • Fujifilm Cellular Dynamics, Inc.
  • Novogene Corporation

Global Immune Repertoire Sequencing Market Report Scope:

  • Historical Data - 2023, 2024
  • Base Year for Estimation - 2024
  • Forecast period - 2025-2035
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Product:

  • Instrument
  • Software
  • Assay Kit & Reagent (TCR Kit, BCR Kit)

By Technology:

  • Sequencing
  • Bioinformatics

By Service:

  • Data Analysis

By Application:

  • Research
  • Drug Discovery & Development

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2025 to 2035.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Immune Repertoire Sequencing Market Report Scope & Methodology

  • 1.1. Research Objective
  • 1.2. Research Methodology
    • 1.2.1. Forecast Model
    • 1.2.2. Desk Research
    • 1.2.3. Top Down and Bottom-Up Approach
  • 1.3. Research Attributes
  • 1.4. Scope of the Study
    • 1.4.1. Market Definition
    • 1.4.2. Market Segmentation
  • 1.5. Research Assumption
    • 1.5.1. Inclusion & Exclusion
    • 1.5.2. Limitations
    • 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

  • 2.1. CEO/CXO Standpoint
  • 2.2. Strategic Insights
  • 2.3. ESG Analysis
  • 2.4. Key Findings

Chapter 3. Global Immune Repertoire Sequencing Market Forces Analysis

  • 3.1. Market Forces Shaping The Global Immune Repertoire Sequencing Market (2024-2035)
  • 3.2. Drivers
    • 3.2.1. Rapid adoption of next-generation sequencing (NGS) for immune profiling
    • 3.2.2. Growing investments in immunology research and precision medicine
  • 3.3. Restraints
    • 3.3.1. High capital and per-sample costs of sequencing and assay workflows
    • 3.3.2. Data complexity, standardization challenges and regulatory hurdles
  • 3.4. Opportunities
    • 3.4.1. Integration of AI/bioinformatics platforms to unlock deeper repertoire insights
    • 3.4.2. Expansion of clinical and translational applications, and growth in APAC research centers

Chapter 4. Global Immune Repertoire Sequencing Industry Analysis

  • 4.1. Porter's 5 Forces Model
    • 4.1.1. Bargaining Power of Buyer
    • 4.1.2. Bargaining Power of Supplier
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Forecast Model (2024-2035)
  • 4.3. PESTEL Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top Investment Opportunities
  • 4.5. Top Winning Strategies (2025)
  • 4.6. Market Share Analysis (2024-2025)
  • 4.7. Global Pricing Analysis And Trends 2025
  • 4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Immune Repertoire Sequencing Market Size & Forecasts by Product 2025-2035

  • 5.1. Market Overview
  • 5.2. Global Immune Repertoire Sequencing Market Performance - Potential Analysis (2025)
  • 5.3. Instrument
    • 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.3.2. Market size analysis, by region, 2025-2035
  • 5.4. Software
    • 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.4.2. Market size analysis, by region, 2025-2035
  • 5.5. Assay Kit & Reagent (TCR Kit, BCR Kit)
    • 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.5.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Immune Repertoire Sequencing Market Size & Forecasts by Technology 2025-2035

  • 6.1. Market Overview
  • 6.2. Global Immune Repertoire Sequencing Market Performance - Potential Analysis (2025)
  • 6.3. Sequencing
    • 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 6.3.2. Market size analysis, by region, 2025-2035
  • 6.4. Bioinformatics
    • 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 6.4.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Immune Repertoire Sequencing Market Size & Forecasts by Service & Application 2025-2035

  • 7.1. Market Overview
  • 7.2. Global Immune Repertoire Sequencing Market Performance - Potential Analysis (2025)
  • 7.3. Service: Data Analysis
    • 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 7.3.2. Market size analysis, by region, 2025-2035
  • 7.4. Application: Research
    • 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 7.4.2. Market size analysis, by region, 2025-2035
  • 7.5. Application: Drug Discovery & Development
    • 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 7.5.2. Market size analysis, by region, 2025-2035

Chapter 8. Global Immune Repertoire Sequencing Market Size & Forecasts by Region 2025-2035

  • 8.1. Immune Repertoire Sequencing Market, Regional Market Snapshot
  • 8.2. Top Leading & Emerging Countries
  • 8.3. North America Immune Repertoire Sequencing Market
    • 8.3.1. U.S. Immune Repertoire Sequencing Market
      • 8.3.1.1. Product breakdown size & forecasts, 2025-2035
      • 8.3.1.2. Application breakdown size & forecasts, 2025-2035
    • 8.3.2. Canada Immune Repertoire Sequencing Market
      • 8.3.2.1. Product breakdown size & forecasts, 2025-2035
      • 8.3.2.2. Application breakdown size & forecasts, 2025-2035
  • 8.4. Europe Immune Repertoire Sequencing Market
    • 8.4.1. UK Immune Repertoire Sequencing Market
      • 8.4.1.1. Product breakdown size & forecasts, 2025-2035
      • 8.4.1.2. Application breakdown size & forecasts, 2025-2035
    • 8.4.2. Germany Immune Repertoire Sequencing Market
      • 8.4.2.1. Product breakdown size & forecasts, 2025-2035
      • 8.4.2.2. Application breakdown size & forecasts, 2025-2035
    • 8.4.3. France Immune Repertoire Sequencing Market
      • 8.4.3.1. Product breakdown size & forecasts, 2025-2035
      • 8.4.3.2. Application breakdown size & forecasts, 2025-2035
    • 8.4.4. Spain Immune Repertoire Sequencing Market
      • 8.4.4.1. Product breakdown size & forecasts, 2025-2035
      • 8.4.4.2. Application breakdown size & forecasts, 2025-2035
    • 8.4.5. Italy Immune Repertoire Sequencing Market
      • 8.4.5.1. Product breakdown size & forecasts, 2025-2035
      • 8.4.5.2. Application breakdown size & forecasts, 2025-2035
    • 8.4.6. Rest of Europe Immune Repertoire Sequencing Market
      • 8.4.6.1. Product breakdown size & forecasts, 2025-2035
      • 8.4.6.2. Application breakdown size & forecasts, 2025-2035
  • 8.5. Asia Pacific Immune Repertoire Sequencing Market
    • 8.5.1. China Immune Repertoire Sequencing Market
      • 8.5.1.1. Product breakdown size & forecasts, 2025-2035
      • 8.5.1.2. Application breakdown size & forecasts, 2025-2035
    • 8.5.2. India Immune Repertoire Sequencing Market
      • 8.5.2.1. Product breakdown size & forecasts, 2025-2035
      • 8.5.2.2. Application breakdown size & forecasts, 2025-2035
    • 8.5.3. Japan Immune Repertoire Sequencing Market
      • 8.5.3.1. Product breakdown size & forecasts, 2025-2035
      • 8.5.3.2. Application breakdown size & forecasts, 2025-2035
    • 8.5.4. Australia Immune Repertoire Sequencing Market
      • 8.5.4.1. Product breakdown size & forecasts, 2025-2035
      • 8.5.4.2. Application breakdown size & forecasts, 2025-2035
    • 8.5.5. South Korea Immune Repertoire Sequencing Market
      • 8.5.5.1. Product breakdown size & forecasts, 2025-2035
      • 8.5.5.2. Application breakdown size & forecasts, 2025-2035
    • 8.5.6. Rest of APAC Immune Repertoire Sequencing Market
      • 8.5.6.1. Product breakdown size & forecasts, 2025-2035
      • 8.5.6.2. Application breakdown size & forecasts, 2025-2035
  • 8.6. Latin America Immune Repertoire Sequencing Market
    • 8.6.1. Brazil Immune Repertoire Sequencing Market
      • 8.6.1.1. Product breakdown size & forecasts, 2025-2035
      • 8.6.1.2. Application breakdown size & forecasts, 2025-2035
    • 8.6.2. Mexico Immune Repertoire Sequencing Market
      • 8.6.2.1. Product breakdown size & forecasts, 2025-2035
      • 8.6.2.2. Application breakdown size & forecasts, 2025-2035
  • 8.7. Middle East and Africa Immune Repertoire Sequencing Market
    • 8.7.1. UAE Immune Repertoire Sequencing Market
      • 8.7.1.1. Product breakdown size & forecasts, 2025-2035
      • 8.7.1.2. Application breakdown size & forecasts, 2025-2035
    • 8.7.2. Saudi Arabia (KSA) Immune Repertoire Sequencing Market
      • 8.7.2.1. Product breakdown size & forecasts, 2025-2035
      • 8.7.2.2. Application breakdown size & forecasts, 2025-2035
    • 8.7.3. South Africa Immune Repertoire Sequencing Market
      • 8.7.3.1. Product breakdown size & forecasts, 2025-2035
      • 8.7.3.2. Application breakdown size & forecasts, 2025-2035

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Adaptive Biotechnologies Corp.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Financial Performance (Subject to Data Availability)
    • 9.2.5. Product/Services Port
    • 9.2.6. Recent Development
    • 9.2.7. Market Strategies
    • 9.2.8. SWOT Analysis
  • 9.3. Bio-Rad Laboratories, Inc.
  • 9.4. Illumina, Inc.
  • 9.5. Thermo Fisher Scientific, Inc.
  • 9.6. Merck KGaA
  • 9.7. Roche Sequencing Solutions
  • 9.8. 10x Genomics, Inc.
  • 9.9. GenScript Biotech Corporation
  • 9.10. New England Biolabs, Inc.
  • 9.11. Agilent Technologies, Inc.
  • 9.12. BD Biosciences
  • 9.13. Tecan Group Ltd.
  • 9.14. Oxford Nanopore Technologies
  • 9.15. Fujifilm Cellular Dynamics, Inc.
  • 9.16. Novogene Corporation
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦